Onconova Therapeutics to Present at the Guggenheim Oncology Conference

Rhea-AI Summary

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on cancer treatment, will participate in the Guggenheim Oncology Conference from February 9-11, 2022. CEO Steven Fruchtman will present a fireside chat on February 10 at 8:30 a.m. ET, available via webcast. Following the presentation, a replay will be archived on Onconova's website. The company will also hold 1x1 meetings on February 9-10, exclusively arranged through Guggenheim. Onconova specializes in developing targeted anti-cancer agents, including the multi-kinase inhibitor narazaciclib and rigosertib for specific cancers.

NEWTOWN, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Guggenheim Oncology Conference taking place virtually February 9, 2022, through February 11, 2022.

Steven Fruchtman, M.D., President & CEO of Onconova, will participate in a fireside chat on February 10, 2022, at 8:30 a.m. ET. A webcast of the fireside chat will be available here. Following the presentation, a replay will be archived on the “Corporate Events and Presentations” section of the Onconova website.

The Company will also be participating in 1x1 meetings February 9, 2022, through February 10, 2022. Meetings can be requested exclusively via Guggenheim.

About Onconova Therapeutics

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors
929-469-3859
bmackle@lifesciadvisors.com

FAQ

What is Onconova's participation in the Guggenheim Oncology Conference 2022?

Onconova Therapeutics will participate in the Guggenheim Oncology Conference from February 9-11, 2022.

When will the CEO of Onconova Therapeutics speak at the conference?

CEO Steven Fruchtman will speak during a fireside chat on February 10, 2022, at 8:30 a.m. ET.

Where can I watch the Onconova fireside chat webcast?

The webcast of the fireside chat can be accessed on Onconova's website after the presentation.

What cancer treatments is Onconova currently developing?

Onconova is developing the multi-kinase inhibitor narazaciclib and rigosertib for various cancers.

How can I request a 1x1 meeting with Onconova at the conference?

1x1 meetings with Onconova can be requested exclusively through Guggenheim during February 9-10, 2022.